News coverage about Ultragenyx Pharmaceutical (NASDAQ:RARE) has been trending positive on Friday, according to AlphaOne Sentiment. The research group, a division of Accern, identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a coverage optimism score of 0.31 on AlphaOne’s scale. AlphaOne also assigned media stories about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted AlphaOne Sentiment Analysis’s rankings:
- The Ultragenyx Pharmaceutical Inc (RARE) Shares Sold by Tocqueville Asset Management LP – BangaloreWeekly (bangaloreweekly.com)
- The Ultragenyx Pharmaceutical Inc (RARE) Receives “Buy” Rating from Citigroup Inc – BangaloreWeekly (bangaloreweekly.com)
- ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Regulation FD Disclosure (4-traders.com)
- ULTRAGENYX PHARMACEUTICAL INC.’s (RARE) registers a price change of 0.45% while Catalyst Pharmaceuticals … – Stocks Gallery (stocksgallery.com)
- Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. – Business Wire (press release) (businesswire.com)
Several equities research analysts have weighed in on RARE shares. Piper Jaffray Companies reissued a “neutral” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 23rd. HC Wainwright cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and dropped their price target for the company from $88.00 to $72.00 in a research report on Wednesday, April 19th. Cowen and Company reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 23rd. Jefferies Group LLC cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating and dropped their price target for the company from $109.00 to $66.00 in a research report on Thursday, April 6th. Finally, SunTrust Banks, Inc. increased their price target on shares of Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, April 19th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $83.00.
Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 2.61% during midday trading on Friday, hitting $57.47. 286,129 shares of the stock traded hands. The company’s market cap is $2.43 billion. The firm’s 50-day moving average is $61.19 and its 200-day moving average is $71.56. Ultragenyx Pharmaceutical has a 52-week low of $46.52 and a 52-week high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.71) by $0.08. During the same quarter in the prior year, the firm earned ($1.35) earnings per share. Analysts predict that Ultragenyx Pharmaceutical will post ($7.02) EPS for the current year.
In other news, insider Theodore Alan Huizenga sold 2,500 shares of the company’s stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $86.34, for a total value of $215,850.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Shalini Sharp sold 12,000 shares of the company’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $90.10, for a total transaction of $1,081,200.00. Following the completion of the sale, the chief financial officer now directly owns 67,887 shares of the company’s stock, valued at $6,116,618.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,500 shares of company stock worth $2,258,730. Company insiders own 10.10% of the company’s stock.
WARNING: “Ultragenyx Pharmaceutical (RARE) Receives Daily Coverage Optimism Score of 0.31” was first reported by Mideast Time and is the sole property of of Mideast Time. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.mideasttime.com/ultragenyx-pharmaceutical-rare-receives-daily-coverage-optimism-score-of-0-31/1708387.html.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.